A program from the American Oncology Network shows promise to introducing cost-efficient biosimilar substitution opportunities to prescribers and payors.A biosimilar substitution program heralded by regional clinical pharmacists was associated with increased use of institution-preferred biosimilar products for the treatment or management of cancer, according to new research that which additionally reported significant cost-savings for all […]
